Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Specimen Handling 219pembrolizumab 199Magnetic Resonance Spectroscopy 197Carboplatin 173Cisplatin 139Biopsy 133Nivolumab 129Paclitaxel 115Radiotherapy 111Cyclophosphamide 111Gemcitabine 104durvalumab 90Dexamethasone 90atezolizumab 76Radiation 72Rituximab 71Lenalidomide 69Pemetrexed 66Doxorubicin 65Bevacizumab 65Docetaxel 62Ipilimumab 58Etoposide 57olaparib 55Fluorouracil 52venetoclax 50Taxes 50Radiosurgery 50Oxaliplatin 50Prednisone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × naporafenib × 90 days × Clear all
NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Novartis

Phase 2 Active not recruiting
134 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡